Exelixis Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EXELIXIS, and what generic alternatives to EXELIXIS drugs are available?
EXELIXIS has two approved drugs.
There are eleven US patents protecting EXELIXIS drugs.
There are two hundred and seven patent family members on EXELIXIS drugs in thirty-two countries and nineteen supplementary protection certificates in sixteen countries.
Drugs and US Patents for Exelixis
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-003 | Apr 25, 2016 | RX | Yes | Yes | 10,034,873 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Exelixis | COMETRIQ | cabozantinib s-malate | CAPSULE;ORAL | 203756-001 | Nov 29, 2012 | RX | Yes | No | 11,091,440 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-002 | Apr 25, 2016 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Exelixis | COMETRIQ | cabozantinib s-malate | CAPSULE;ORAL | 203756-001 | Nov 29, 2012 | RX | Yes | No | 11,298,349 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Exelixis Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Serbia | 52754 | ⤷ Try a Trial |
Australia | 2012214322 | ⤷ Try a Trial |
South Africa | 201300458 | ⤷ Try a Trial |
Denmark | 2210607 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Exelixis Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2213661 | PA2014033 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: CABOZANTINIBUM; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140321 |
2213661 | C20140029 00117 | Estonia | ⤷ Try a Trial | PRODUCT NAME: KABOSANTINIIB;REG NO/DATE: K(2014)2043 (LOPLIK) 26.03.2014 |
2213661 | SPC/GB14/052 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: CABOZANTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/13/890/001-006 20140326 |
2213661 | 1490053-4 | Sweden | ⤷ Try a Trial | PRODUCT NAME: CABOZANTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/13/890 20140326 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.